NVS
Novartis AG$150.88
LiveJun 17, 2026
Market cap
$287.89B
52w range
112.34 – 170.46
P / E
—
EPS
—
Volume
1.57M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Novartis AG’s valuation06-04today
- Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study2d
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)5d
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)5d
- Novartis says rare muscle disease drug shows promise in early trial6d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $141.00 (-6.55%)
Candlestick · 1Y
Open in chart workstation →NVS
151.56+30.20%H 170.46L 112.34MA50 149.28MA200 141.80Avg vol 1.8M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.03% | -1.98% | +1.89% | -2.56% | +11.74% | +9.44% | +29.61% | +58.16% | +69.36% | +131.48% | +859.19% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$150.88
189 sh
Bid
$148.00
10 sh
Ask
$152.98
8 sh
Spread
$4.980
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Utilities+3.33%
- Financial Services+0.02%
- Industrials-0.12%
- Healthcare-0.72%
- Energy-0.94%
- Technology-0.95%
- Consumer Defensive-1.52%
- Basic Materials-1.60%
- Consumer Cyclical-1.74%
- Communication Services-1.79%
- Real Estate-2.19%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.39%
- Auto - Dealerships-6.22%
- Trucking-5.25%
- Renewable Utilities+5.11%
- Oil & Gas Energy-4.86%
- Consulting Services-4.82%
- Financial - Mortgages-4.15%
- REIT - Office-3.71%
- Software - Application-3.50%
- Medical - Healthcare Information Services-3.48%
- Grocery Stores-3.45%
- Discount Stores-3.44%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$141.00
-6.55% upside
Low
$112.00
Median
$141.00
High
$170.00
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Studyzacks.com·Jun 15, 2026
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)globenewswire.com·Jun 12, 2026
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)globenewswire.com·Jun 12, 2026
- Novartis says rare muscle disease drug shows promise in early trialreuters.com·Jun 11, 2026
- Novartis Reports Positive Data for Neuromuscular Disorder Drugzacks.com·Jun 11, 2026
- Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Studybenzinga.com·Jun 11, 2026
- Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointglobenewswire.com·Jun 11, 2026
- Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointglobenewswire.com·Jun 11, 2026
Peers
No peer list available for NVS.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|